European stocks fell, following yesterday�� rally for the Stoxx Europe 600 Index, as a report showed that U.K. construction expanded less than forecast.
Fresenius Medical Care AG plunged the most in more than a decade as the U.S. Medicare program proposed cutting spending on dialysis. Telefonica Deutschland Holding AG lost 1.7 percent as Commerzbank AG lowered its recommendation for the mobile-phone operator. Dialog Semiconductor Plc rose 7.6 percent after the German maker of chips used in Apple Inc.�� iPhone agreed to buy IWatt Inc. for as much as $345 million.
The Stoxx 600 slipped 0.4 percent to 287.13 at the close of trading. The equity benchmark advanced yesterday as euro-area factory output contracted in June less than estimated and Japanese manufacturers turned optimistic for the first time since the third quarter of 2011.
��arkets need a major catalyst to revive the uptrend,�� said Benedict Goette, chief executive officer of Compass Capital AG in Zurich, which helps oversee about 700 million Swiss francs ($737 million). ��e expect that the correction will continue.��
Top 5 Forestry Stocks To Own For 2015: Revive Therapeutics Ltd (RVV)
Revive Therapeutics Ltd., formerly Mercury Capital II Limited, is focused on acquiring, developing and commercializing treatments for major market opportunities such as sleep apnea, gout and rare diseases. The Company is focused on underserved medical needs such as opioid-induced respiratory depression in high risk patients with sleep apnea, gout, and Rett Syndrome. The Company is also developing a next generation analog of REV-001, which is an improvement of the original compound and it will have the potential to treat new diseases that would otherwise remain untreated with the original compound, such as rare diseases, breathing disorders, and cognitive dysfunction. Advisors' Opinion:- [By Holly LaFon]
Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.
Hot Japanese Companies To Buy For 2014: Fusion-io Inc (FIO)
Fusion-io Inc (Fusion) is a provider of datacenter solutions that accelerate databases, virtualization, cloud computing, big data, and the applications that help drive business from the smallest e-tailers to some of the largest data centers, social media leaders, and Fortune Global 500 businesses. The Company's integrated hardware and software platform enables the decentralization of data from legacy architectures and specialized hardware. The Company sells its solutions through a global direct sales force, original equipment manufacturers, or OEMs, including Cisco, Dell, HP, and IBM, and other channel partners. In August 2011, the Company acquired IO Turbine, Inc.,. Effective March 18, 2013, the Company acquired ID7.
Fusion-io's ioMemory hardware is a sub-system connecting a large array of industry-standard NAND Flash memory through the Company's data-path controller and its virtual storage layer, or VSL, software to create a high capacity memory tier that natively attaches to a server's PCI-Express peripheral bus (PCIe).
The Company's portfolio of storage memory products incorporates the Company's ioMemory hardware combined with its virtual storage layer (VSL) and caching software into its family of ioDrive, ioFX, and ioCache enterprise grade products. The Company's ioDrive products work in conjunction with the Company's directCache data-tiering software, ioTurbine virtualization software, ioSphere management system, and ION Data Accelerator software. The Company's latest ioDrive, ioFX, and ioCache product families are a line of PCIe standard form-factor storage memory platforms that combine one or more ioMemory sub-systems with the Company's VSL software.
The Company's directCache software extends the Company's ioMemory based platforms and permits interoperability with traditional direct-attached, network-attached, storage area network attached, and appliance attached backend storage systems. The Company's ioTurbine virtualization software extends the Company! 's ioMemory platform and permits host-based data acceleration to specifically address the demand for high-density, high-performance server, and desktop virtualization.
ioSphere is a suite of management software purpose-built for the Company's storage memory infrastructure and designed around its application acceleration platform. ioSphere software is accessible through a graphical user interface that enables datacenter administrators to centrally configure, monitor, manage, and tune all distributed ioMemory devices throughout the datacenter. In addition, this software offers real-time, predictive, and historical reporting of ioMemory's performance and wear.
The Company's ION Data Accelerator software transforms server platforms into application acceleration appliances that share Fusion ioMemory across applications. ION Data Accelerator delivers Fusion-io performance on open server platforms with software-defined storage, or SDS, for applications such as Oracle RAC, Microsoft SQL Server, MySQL, and SAP HANA, along with other applications where shared storage aids deployment. The Company's original equipment manufacturer�� (OEMs), including Cisco, Dell, HP, and IBM, sell branded storage memory solutions based on the Company's standard products as well as custom form-factor versions to fit specific applications.
The Company competes with EMC Corporation, Hewlett-Packard Development Company, L.P, Texas Memory Systems, Oracle, Adaptec, Inc., LSI Corporation, Sandisk, Corp, IBM, CA, Inc, Nagios Enterprises, LLC., Hitachi Data, Huawei Technologies, Co., Intel Corp., LSI Corporation, Marvell Semiconductor, Inc., Micron Technology, Inc., OCZ Technology Group, Inc., Samsung Electronics, Inc., SanDisk, Corp., Seagate Technology, STEC, Inc., Toshiba Corp., and Western Digital Corp.
Advisors' Opinion:- [By Lisa Levin]
Fusion-io (NYSE: FIO) shares jumped 14.75% to $10.81 on stronger-than-expected quarterly results.
Posted-In: market moversNews Intraday Update Markets Movers
Hot Japanese Companies To Buy For 2014: Seattle Genetics Inc.(SGEN)
Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Advisors' Opinion:- [By Roberto Pedone]
One biotechnology player that insiders are snapping up a huge amount of stock in here is Seattle Genetics (SGEN), which develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Insiders are buying this stock into huge strength, since shares are up sharply by 72% so far in 2013.
Seattle Genetics has a market cap of $4.9 billion and an enterprise value of $4.5 billion. This stock trades at a premium valuation, with a price-to-sales of 19.09 and a price-to-book of 21.65. Its estimated growth rate for this year is -37%, and for next year it's pegged at -6.3%. This is a cash-rich company, since the total cash position on its balance sheet is $373.85 million and its total debt is zero.
A director just bought 1,005,901 shares, or about $43.44 million worth of stock, at $42.31 to $43.98 per share.
From a technical perspective, SGEN is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares dropping from its high of $45.37 to its intraday low of $39.85 a share. During that move, shares of SGEN have been consistently making lower highs and lower lows, which is bearish technical price action.
If you're bullish on SGEN, then I would look for long-biased trades as long as this stock is trending above its 200-day of $38.40 or above more near-term support at $36.79 and then once it takes out its 50-day at $41.02 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 856,995 shares. If we get that move soon, then SGEN will set up to re-test or possibly take out its next major overhead resistance levels at $45.37 $46.48 a share. Any high-volume move above those levels will then give SGEN a chance to tag its 52-week high at $49.23 a share.
Hot Japanese Companies To Buy For 2014: Texas Rare Earth Resources Corp (TRER.PK)
Texas Rare Earth Resources Corp., formerly Standard Silver Corporation, incorporated on July 29, 1970. a mining company engaged in the business of the acquisition and development of mineral properties. As of August 31, 2012, it held a nineteen year lease to explore and develop a 950 acre rare earth uranium-beryllium prospect located in Hudspeth County, Texas known as Round Top and prospecting permits covering an adjacent 9,345 acres.
The Company�� principal focus will be on developing a metallurgical process to concentrate or otherwise extract the metals from the Round Top rhyolite. In addition to the Round Top Project, the Company also own title to 12 unpatented mining claims, the Macho group, comprising 240 acres covering the Old Dude Mine, located in Sierra County, New Mexico. Another 18 unpatented mining claims and fractional claims, the HA group, consisting 274 acres cover an andesite hosted vein system similar to and some 10 miles to the southwest of the Macho District.
Advisors' Opinion:- [By Jake Mitchell]
As a speculative play on the industry, I came across Texas Rare Earth Resources (TRER.PK), which is principally focused on its 950 acre Round Top project. A Preliminary Economic Assessment by an independent third party found that there are an estimated over 1 billion metric tonnes of resources containing over 1 billion pounds of rare earth elements. A revised PEA, which was originally projected to have a capital cost of $2.1 billion is now estimated to be between $150 million to $350 million. A key concern in the exploration of these mines is how expensive it is to ultimately extract the rare earths from the ground. If Texas Rare Earth is able to show evidence that cost has been significantly reduced it will be the target of interested parties globally.
Hot Japanese Companies To Buy For 2014: Horizon Technology Finance Corporation (HRZN)
Horizon Technology Finance Corporation, a specialty finance company, lends to and invests in development-stage companies in the United States. It provides secured loans to companies backed by established venture capital and private equity firms in the technology, life science, healthcare information and services, and cleantech industries. Horizon Technology Finance Corporation was founded in 2008 and is based in Farmington, Connecticut.
Advisors' Opinion:- [By BDC Buzz]
I believe investors should look past the current low dividend yields and relatively higher multiples of NAV per share for BDCs such as FDUS, MAIN, and TCAP, but should consider the total return for these companies. The table below compares FDUS and MAIN to both ACAS which does not pay dividends and Horizon Technology Finance (HRZN) that pays a higher than average dividend but after taking into account dividend growth, special dividends, and NAV per share growth (using last twelve months actual for projection purposes) it is clear that the expected investor return is based on more than the current dividend yield.
No comments:
Post a Comment